The purpose of this study is to evaluate the effects of an FDA-approved medication called tolcapone in people who have both Alcohol Use Disorder (AUD) and Attention-Deficit/Hyperactivity Disorder (ADHD). The study involves seven visits over a three to four week period, including an assessment visit and two eight-day medication periods during which participants will be assigned to take, in a double-blinded fashion, both tolcapone and a placebo (three visits during each period). During two of these visits, participants will undergo a one-hour MRI scan. Participants must not be seeking treatment for AUD or ADHD and must not be currently taking any psychotropic medications, including stimulant medications for ADHD. Compensation is available for qualified participants.
This study will examine the effects of Epidiolex among adults who drink alcohol heavily but who are not seeking treatment for their alcohol use. Epidiolex is an FDA-approved formulation of cannabidiol, the primary non-psychoactive constituent of cannabis. Participants in the study will be randomly assigned to take Epidiolex or placebo for 8 days. There are 3 study visits, including a day-long visit in the laboratory.
This study examines the effects of the medication tolcapone among individuals who regularly drink alcohol. Participants in this study will be randomly assigned to take either tolcapone or a matched placebo for 8 days. There are 3 study visits, including 2 MRI scans, and a debriefing session. This study does not involve alcohol treatment. Interested individuals must be referred for participation by the Charleston Alcohol Research Center Clinical Intake and Assessment Core. For more information, call 792-1222 or email firstname.lastname@example.org.